SOME MECHANISMS OF LACTOBACILLUS REUTERI ACTION AS A PROBIOTIC MICROORGANISM

2022;
: 127-132
1
Lviv Polytechnic National University
2
Lviv Polytechnic National University
3
Lviv Polytechnic National University
4
Lviv Polytechnic National University

Some morphological, physiological and biochemical characteristics of the probiotic species of lactic acid bacteria Lactobacillus reuteri are presented in the work. This species, according to literature sources, were isolated from the normal human microbiota, other members of the class Mammalia, as well as broilers and sourdough. The study of literature and Internet sources identified the importance of using different strains of L. reuteri in modern dietary supplements.Some physiological features of this microorganism in terms of positive effects on the functioning of the human gastrointestinal tract and the formation of immunity were considered. According to processed datait is concluded that there is a necessity for further practical study of L. reuteri as a potential probiotic for the pharmaceutical and food industries.

1. Hou C., Zeng X., Yang F. et all. (2015). Study and use of the probiotic Lactobacillus reuteri in pigs: a review. Journal of animal science and biotechnology. №6. P. 156-160
https://doi.org/10.1186/s40104-015-0014-3
2. Sung V., Hiscock H., Tang M. et all. (2014) Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. An J Physiol Gastrointest Liver Physiol. P. H988-H994
https://doi.org/10.1136/bmj.g2107
3.  Mu Q., V. Tavella V., Luo X. (2018). Role of Lactobscillus reuteri in human health and diseases. Frontiers in Microbiology. №9. P. 124-130
https://doi.org/10.3389/fmicb.2018.00757
4. Liu Y., Fatheree N., Mangalat N., Rhoads J. (2010). Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. An J Physiol Gastrointest Liver Physiol. P. G1087-G1096.
https://doi.org/10.1152/ajpgi.00124.2010
5. Thomas C., Hong T., J. van Pijkeren et all. (2012). Histamine Derived from Probiotic Lactobacillus reuteri Suppresses TNF via Modulation of PKA and ERK Signaling . PLoS ONE. P. 244-230
https://doi.org/10.1371/journal.pone.0031951
6. Iyer C., Kosters A., Sethi G. et all. (2008). Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kB and MAPK signalling. Cellular Microbiology. №10. P. 1442-1452.
https://doi.org/10.1111/j.1462-5822.2008.01137.x
7. Sung V., D'Amico F., Cabana M. (2018). Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. Pediatrics. No.2. P. 233-238
https://doi.org/10.1542/peds.2017-1811
8. Versalovic J., Jones S. (2009). Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiology. P. 1012-1017
9. Mukai T., Asasaka T., Sato E. et all. (2002). Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunology and Medical Microbiology. №32. P. 105-110
https://doi.org/10.1111/j.1574-695X.2002.tb00541.x
10. Taranto M., Vera J., Hugenholtz J. et all. (2003). Lactobacillus reuteri CRL1098 Produces Cobalamin. American Society for Microbiology. P. 5643-5647
https://doi.org/10.1128/JB.185.18.5643-5647.2003
11. Gänzle M., Höltzel A., Walter J. et all. (2000). Characterization of Reutericyclin Produced by Lactobacillus reuteri LTH2584. Applied and environmental microbiology. P. 4325-4333
https://doi.org/10.1128/AEM.66.10.4325-4333.2000
12. Valeur N., Engel P., Carbajal N. et all. (2004). Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract. Applied and Environmental Microbiology. P. 1176-1181
https://doi.org/10.1128/AEM.70.2.1176-1181.2004
13. Forsythe P., Inman M., Bienenstock J. (2006). Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice . American Journal Of Respiratory And Critical Care Medicine. P. 561-569
https://doi.org/10.1164/rccm.200606-821OC
14. Jones M., Martoni C., Parent M., Prakash S. (2012). Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.  British Journal of Nutrition. P.1505-1513
https://doi.org/10.1017/S0007114511004703
15.  Sinkiewicz G., Ljunggren L. Occurrence of Lactobacillus reuteri in human breast milk. (2009) Microbial Ecology in Health and Disease. P. 122-126
https://doi.org/10.1080/08910600802341007
16. Axelsson L., Chung T., Dobrogosz W., Lindgren S. (1989). Production of a Broad Spectrum Antimicrobial Substance by Lactobacillus reuteri. Microbial Ecology in Health and Disease. P. 131-136
https://doi.org/10.3109/08910608909140210
17.  Axelsson L., Chung T., Dobrogosz W., Lindgren S. (1989). In Vitro Studies on Reuterin Synthesis by Lactobacillus reuteri. Microbial Ecology in Health and Disease. P. 137-144
https://doi.org/10.3109/08910608909140211
18. Vicario M., Santos A., Violant D. et all. (2013). Clinical changes in periodontal subjects with the probiotic Lactobacillus reuteri Prodentis: A preliminary randomized clinical trial. Acta Odontologica Scandinavica. P. 813-819
https://doi.org/10.3109/00016357.2012.734404
19. Jones M., Martoni C., Parent M., Prakash S. (1988). Production and Isolation of Reuterin, a Growth Inhibitor Produced by Lactobacillus reuteri. Antimicrobial Agents And Chemotherapy. P.1854-1858
https://doi.org/10.1128/AAC.32.12.1854
20. Talarico T., Dobrogosz W. (1989). Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri.  Antimicrobial Agents And Chemotherapy. P. 674-679
https://doi.org/10.1128/AAC.33.5.674
21. Martin H. Floch, Yehuda Ringel and W. Allan Walker The microbiota in gastrointestinal pathophysiology. - B.: Academic Press, 2017. - Ch. 8, P. 89-97
22. Chervetsova V.H., Dmytriv A.Z., Shved O.V., Konechna R.T., Lubenetsʹ V.I. Analiz vykorys-tannya Lactobacillus reuteri yak probiotyka. P. 254-266. in Traditional medicine and pharmacology. Achievements, innovation, and alternatives: collective monograph Gryschenko V., - etc. - International Science Group. - Boston: Primedia eLaunch, 2021. 327 p. DOI - 10.46299/ISG.2021.MONO.MED.II  
https://doi.org/10.46299/ISG.2021.MONO.MED.II-254-266